Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
Galectin Therapeutics Inc. (GALT) had Debt to Equity Ratio of -1.04 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-5.07M |
|
-- |
|
-- |
|
$4.08M |
|
$-4.08M |
|
$-0.97M |
|
$-5.05M |
|
$-5.05M |
|
$-5.05M |
|
$-5.05M |
|
$-5.05M |
|
$-5.05M |
|
$-4.08M |
|
$-4.07M |
|
65.78M |
|
65.78M |
|
$-0.08 |
|
$-0.08 |
|
| Balance Sheet Financials | |
$15.69M |
|
-- |
|
$0.07M |
|
$15.76M |
|
$7.31M |
|
$135.71M |
|
$138.69M |
|
$146.00M |
|
$-132.44M |
|
$-130.24M |
|
$-130.24M |
|
65.86M |
|
| Cash Flow Statement Financials | |
$-3.87M |
|
-- |
|
$0.26M |
|
$17.72M |
|
$14.11M |
|
$-3.61M |
|
$0.69M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.15 |
|
-- |
|
-- |
|
24.80 |
|
|
Debt to Equity Ratio |
-1.04 |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.87M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
3.81% |
|
3.87% |
|
-32.02% |
|
-92.20% |
|
$-1.98 |
|
$-0.06 |
|
$-0.06 |
|